VCIM
JSPR icon

Velan Capital Investment Management’s Jasper Therapeutics JSPR Stock Holding History

Velan Capital Investment Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Hold
2,668,395
– – 0.68% 23
2026
Q1 		$2.34M Hold
2,668,395
– – 1.46% 19
2025
Q4 		$4.88M Hold
2,668,395
– – 2.83% 10
2025
Q3 		$6.21M Buy
2,668,395
+1,234,567
+86% +$3.74M 5.83% 7
2025
Q2 		$7.96M Hold
1,433,828
– – 7.86% 3
2025
Q1 		$6.17M Hold
1,433,828
– – 6.34% 7
2024
Q4 		$30.7M Hold
1,433,828
– – 26.45% 1
2024
Q3 		$27M Sell
1,433,828
-38,076
-3% -$758K 25.22% 1
2024
Q2 		$32.5M Hold
1,471,904
– – 18.65% 2
2024
Q1 		$42.1M Buy
1,471,904
+350,000
+31% +$6.22M 19.12% 2
2023
Q4 		$8.55M Hold
1,121,904
– – 4.99% 5
2023
Q3 		$7.59M Hold
1,121,904
– – 6.12% 3
2023
Q2 		$14.8M Hold
1,121,904
– – 13.79% 1
2023
Q1 		$19.6M Buy
1,121,904
+800,000
+249% +$14.8M 16.72% 1
2022
Q4 		$1.37M Hold
321,904
– – 1.21% 17
2022
Q3 		$2.24M Hold
321,904
– – 2.22% 12
2022
Q2 		$5.48M Hold
321,904
– – 5.56% 6
2022
Q1 		$10.2M Hold
321,904
– – 9.45% 4
2021
Q4 		$22.9M Buy
+321,904
New +$30.1M 17.81% 1

Other funds holding JSPR

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Velan Capital Investment Management's JSPR Position: Q2 2026 in Review

Velan Capital Investment Management held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 2,668,395 shares worth $1.12M. The position accounts for 0.68% of the portfolio, ranked #23.

Velan Capital Investment Management first reported a position in JSPR in Q4 2021 and has held it in 19 quarters since. The position peaked at $42.1M in Q1 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Velan Capital Investment Management held 2,668,395 shares of Jasper Therapeutics worth $1.12M as of Q2 2026.
  • Velan Capital Investment Management left its Jasper Therapeutics share count unchanged in Q2 2026.
  • Jasper Therapeutics made up 0.68% of Velan Capital Investment Management's portfolio in Q2 2026, its #23 holding.
  • Velan Capital Investment Management first reported a position in Jasper Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Velan Capital Investment Management's Jasper Therapeutics position peaked at $42.1M in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Velan Capital Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.